-
Jan 16 |
Diagnostics World News | Grail returned to the 44th Annual J.P. Morgan Healthcare Conference for its second appearance as an independent public company, and CEO Bob Ragusa had positive momentum to report, though the tipping point is still expecting mid-2026 with the readouts of two major clinical trials. The multi-cancer early detection company is closing in on a critical regulatory milestone while demonstrating strong commercial traction.
More
-
Jan 14 |
Diagnostics World News | Researchers in the University of Surry (UK) have identified a set of blood-based protein signals that may foreshadow an individual’s risk of death five to 10 years before it occurs. This discovery carries promise for next-generation diagnostics aimed at early risk detection rather than disease diagnosis.
More
-
Jan 12 |
Diagnostics World News | Grail returned to the 44th Annual J.P. Morgan Healthcare Conference for its second appearance as an independent public company, and CEO Bob Ragusa had positive momentum to report, though the tipping point is still expecting mid-2026 with the readouts of two major clinical trials. The multi-cancer early detection company is closing in on a critical regulatory milestone while demonstrating strong commercial traction.
More
-
Jan 09 |
Diagnostics World News | There can be little debate that Alzheimer’s disease is one of the greatest healthcare challenges we face globally. Most recent estimates suggest that over 57 million people worldwide are living with dementia, of which 70% is caused by Alzheimer’s. With aging societies, this number is expected to increase to over 150 million by 2050. Yet there is a growing sense of impending change, particularly because the way we diagnose Alzheimer’s is now at a pivotal moment.
More
-
Jan 08 |
Diagnostics World News | In just a few years, the monitoring of brain signals via ubiquitous earbuds will be as common as heart rhythm tracking by popular smartwatch brands like Apple and Fitbit. People wearing these next-generation earbuds will have their electroencephalogram (EEG) effortlessly analyzed while they listen to music or make phone calls.
More
-
Jan 07 |
Diagnostics World News | After less than three years of collecting voice samples from individuals with amyotrophic lateral sclerosis, and a control group of healthy volunteers, the Peter Cohen Foundation awaits approval from the Food and Drug Administration of its algorithm as a secondary biomarker for tracking the progression of the devastating neurological disease. The drug development tool, a “listener effort” prediction model, will be used in a multitude of clinical trials as soon as the first quarter of 2026.
More
-
Jan 06 |
Diagnostics World News | To kick off 2026, we spoke with industry experts and leaders in the Diagnostics World community about what they expect and look forward to in the new year. Here are the full trends and predictions, including more on AI, data management and collection, precision diagnostics, new testing, and more.
More
-
Dec 29 |
Diagnostics World News | Diagnostics is gaining growing traction within several companies not historically diagnostics-focused, and it is the subject of a fair amount of AI investment as well. NVIDIA’s partnerships with diagnostics companies came up in more than one top story of the year, and AI’s role for image processing came up in others. Even earlier multi-cancer early detection tests were notable and the growing trend in women’s health was reflected in attention to endometriosis diagnosis.
More
-
Dec 23 |
Diagnostics World News | Circular Genomics will accelerate the clinical development and commercialization of their circRNA biomarker platform for the early detection of Alzheimer's disease; Wearlinq introduces eWave, the first continuous, multi-lead (6-lead) ECG in a small, wireless form factor; Subsense is building a bidirectional BCI platform designed to record and modulate brain activity without surgical implants; and more.
More
-
Dec 22 |
Diagnostics World News | The Singapore-MIT Alliance for Research and Technology launches a new collaborative research project; Cleveland Diagnostics receives FDA approval of their IsoPSA in vitro diagnostic kit; Roche announces that its first point-of-care test for the detection of Bordetella infections has been granted FDA 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 waiver; and more.
More
-
Jan 14 |
Gifthealth has announced the appointment of Jeremy Richardson as its new Chief Commercial Officer (CCO).
More
-
Jan 14 |
Strategic appointment to support global scale-up of sample management operations
More
-
Jan 14 |
More
-
Jan 12 |
Cycle and Inceptua have announced the expansion of their partnership to make NITYR® tablets available via a Free Goods Programme for eligible patients with HT-1 and AKU to include Morocco and Egypt.
More
-
Jan 12 |
More
-
Jan 08 |
More
-
Jan 07 |
PharmaForceIQ has announced its acquisition of Aktana, aligning its cutting-edge digital orchestration platform with the industry’s premier AI-driven field Next-Best-Action (NBA) platform.
More
-
Dec 17 |
The first START site in New York launches a new strategic partnership to provide cutting-edge cancer research.
More
-
Dec 15 |
Built directly into the elluminate ecosystem, the agents combine governed data with explainable intelligence to accelerate decisions
More
-
Dec 15 |
CluePoints, provider of leading statistical and AI-driven software solutions, has won the ‘Best Contract Research Organization– Specialist Providers’ category at the 2025 Scrip Awards.
More
View more articles